Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi(Université de Lille), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), John Staffurth(Velindre NHS Trust), Jin Hui Li(Janssen (United States)), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Robert J. Jones(Beatson West of Scotland Cancer Centre), Fred Saad(Centre Hospitalier de l’Université de Montréal), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Thian Kheoh(Janssen (United States)), Scott North, Howard I. Scher(Memorial Sloan Kettering Cancer Center), Oscar B. Goodman(Roseman University of Health Sciences), Arturo Molina(Janssen (United States)), Stephen Harland(CRUK Lung Cancer Centre of Excellence), Cora N. Sternberg(Cornell University), Christopher M. Haqq(Unknown), Kim N.(Asian Institute of Technology)
Cited by 1,383
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k